Opioids and the Toxic Unregulated Drug Supply
Drugs and Society
Learning objectives for this lesson:
- Distinguish natural opiates, semi-synthetic opioids, synthetic opioids and novel synthetic opioids, and state their legal status under Canada's Controlled Drugs and Substances Act as of September 2026.
- Explain how the endogenous opioid system and the mu-opioid receptor work, how activating the receptor produces pain relief, euphoria, sedation and slowed breathing, and how full agonists, partial agonists and antagonists differ in their action at it.
- Compare the potency, timing and Canadian presence of morphine, heroin, fentanyl, carfentanil and nitazene opioids, and calculate relative potency as a ratio.
- Explain the triple wave model of the overdose crisis, describe, with dated Canadian figures, how illicitly manufactured fentanyl and then fentanyl analogues came to dominate the unregulated supply, and explain why a 2021 review and a 2019 RAND report attribute the shift mainly to suppliers.
- Explain why Canadian agencies name and count drug deaths differently, and compare the sources that monitor the composition of the unregulated drug supply in Canada, stating a strength and a limit of each.
- Explain how xylazine, medetomidine and nonmedical benzodiazepines act, how medetomidine displaced xylazine between 2024 and 2026, and what harms each class brings.
- Explain how opioids depress breathing and how naloxone reverses them as a competitive antagonist, using a simple receptor-share ratio to show why repeated doses may be needed.
- Explain why naloxone restores breathing but not alertness when sedative adulterants are present, and why the weeks after release from prison carry a high risk of overdose death.
This course was developed by Dr. Kiffer G. Card.
Opioid Receptors, Endogenous Opioids and Opioid Potency
Content note. This section discusses opioid overdose and drug toxicity deaths. If you would like support, the 9-8-8 Suicide Crisis Helpline is available by call or text at 9-8-8, the National Overdose Response Service can be reached at 1-888-688-6677, and the Hope for Wellness Help Line for Indigenous people can be reached at 1-855-242-3310.
Introduction
Opioids are among the oldest medicines in human use and among the drugs most closely tied to death in Canada over the past decade. The same molecule that relieves severe pain after surgery can stop a person's breathing when the amount is too large or when it is combined with other sedating drugs. Between January 2016 and March 2026, the Public Health Agency of Canada counted 57,509 apparent opioid toxicity deaths in Canada (Public Health Agency of Canada [PHAC], 2026). Understanding why these drugs are so useful and so dangerous begins at the level of a single receptor protein in the membrane of a nerve cell.
Lesson 3 introduced the shared vocabulary of pharmacology: receptors, agonists and antagonists, potency, half-life and tolerance. This section applies it to the opioids, moving from the opioid family and its legal status to the body's own opioid system, the mu-opioid receptor, five opioids that matter in the Canadian supply, and finally potency, the property that makes very small amounts of fentanyl, carfentanil and nitazenes so consequential.
Learning Objectives
- 1.1 Distinguish natural opiates, semi-synthetic opioids, synthetic opioids and novel synthetic opioids, and state where the main opioids sit in Canada's Controlled Drugs and Substances Act as of September 2026.
- 2.1 Describe the endogenous opioid system, naming the mu, delta, kappa and nociceptin receptors and the endorphins, enkephalins and dynorphins that act on them.
- 2.2 Explain how activation of the mu-opioid receptor quiets nerve cells and produces pain relief, euphoria, sedation, constricted pupils, constipation and slowed breathing.
- 2.3 Distinguish full agonists, partial agonists and antagonists at the mu-opioid receptor, and explain how tolerance changes the effect of a given amount of opioid.
- 3.1 Compare morphine, heroin, fentanyl, carfentanil and nitazene opioids on potency, timing and presence in the Canadian unregulated supply, using cited figures.
- 3.2 Calculate relative potency as a ratio, explain why potency, which concerns mass, differs from efficacy, which concerns the largest effect a drug can produce, and explain why high potency is dangerous in an unregulated supply.
1.1 Opiates, Opioids and Their Legal Status
The words opiate and opioid are often used interchangeably, but they began with different meanings. An opiate is a compound found naturally in the opium poppy, such as morphine and codeine. An opioid is any substance, natural or manufactured, that acts on the body's opioid receptors. Every opiate is therefore an opioid, while fentanyl and many other opioids never came from a poppy. This lesson uses opioid as the general term.
1.1.1 Four Families of Opioid Drugs
Pharmacologists group opioid drugs by how they are made. The German pharmacist Friedrich Sertürner isolated morphine from opium in 1805 (Ciccarone, 2019); chemists later modified morphine to make semi-synthetic opioids, and in the twentieth century built fully synthetic molecules that act on the same receptors. The flip cards below summarize the four families used in this lesson; click each card to read its description.
1.1.2 Legal Status in Canada
Canada controls opioids through the Controlled Drugs and Substances Act of 1996, which sorts controlled substances into schedules. Lesson 11 develops how scheduling works and how it has been used. In the version of the Act current to 30 September 2026, Schedule I lists the opium poppy and its alkaloids and derivatives, naming opium, codeine, morphine and diacetylmorphine (heroin). The same schedule lists fentanyl and its analogues, naming carfentanil and para-fluorofentanyl, and a group of benzimidazoles that includes etonitazene, a nitazene (Controlled Drugs and Substances Act, 1996). Morphine and fentanyl are also prescription medicines, so the same molecule can be a legal medicine in a hospital and an illegal drug when made and sold outside regulated channels, an example of the legal construction of drug categories described in Lesson 1.
The legal schedule says nothing about how an opioid acts, so the next part turns to the receptors on which opioids act.
2.1 The Body's Own Opioids and Their Receptors
Opioid drugs work because the nervous system already contains an opioid signalling system, in which nerve cells release small proteins, called peptides, that bind to opioid receptors. Opioid drugs act on these receptors in place of the body's own peptides. This part describes how the system was found and what its parts are.
2.1.1 Discovering the Receptors and Their Natural Partners
Why a plant chemical should have such strong effects on people was explained in two steps in the 1970s, which the box below summarizes. Both relied on naloxone, a drug that blocks opioid receptors and returns in Section 4.
Finding the opioid receptor and the enkephalins
In 1973, Candace Pert and Solomon Snyder attached a radioactive label to naloxone and showed that it bound specifically to an opiate receptor in mammalian brain tissue and in guinea pig intestine. Different opiates and their antagonists competed for this receptor, and the strength of their competition closely paralleled their known pharmacological potency (Pert & Snyder, 1973). The finding implied that the brain makes its own chemicals for the receptor, and in 1975 John Hughes, Hans Kosterlitz and colleagues identified two of them, short peptides they called enkephalins (Hughes et al., 1975). Beta-endorphin and the dynorphins were identified soon after.
2.1.2 Four Receptor Types
Opioid receptors come in several types, each with preferred natural partners. All of them are G protein-coupled receptors, a large family of receptor proteins that pass a message from outside the cell to a group of signalling proteins (G proteins) inside it (Dhaliwal & Gupta, 2023). Table 5.1 lists the four receptor types that are best described, with the endogenous peptides that bind to each.
Table 5.1. The four main opioid receptor types, their principal endogenous ligands, and their relevance to this lesson (receptor and ligand information from Dhaliwal & Gupta, 2023).
| Receptor | Main endogenous ligands | Relevance in this lesson |
|---|---|---|
| Mu (MOR) | Beta-endorphin, endomorphin-1 and endomorphin-2 | The main target of morphine, heroin, fentanyl, carfentanil and the nitazenes, and the receptor through which opioids slow breathing |
| Delta (DOR) | Enkephalins | Part of the same signalling system; less central to overdose |
| Kappa (KOR) | Dynorphin A and dynorphin B | Part of the same signalling system; less central to overdose |
| Nociceptin (NOP) | Nociceptin, also called orphanin FQ | A related receptor with its own peptide |
The mu-opioid receptor matters most for this lesson, because opioid medicines and the opioids in the unregulated supply produce their main effects by activating it. Opioid receptors are also found in brainstem regions that generate breathing (Stucke et al., 2023), which Section 4 develops.
2.2 What Happens When a Mu Receptor Is Activated
Activating a mu-opioid receptor makes a nerve cell quieter. The receptor switches on inhibitory G proteins inside the cell, which have three main effects (Dhaliwal & Gupta, 2023). They lower the level of an internal messenger called cyclic AMP by inhibiting the enzyme adenylate cyclase. They open potassium channels, so positive ions flow out and the cell becomes more negative inside (hyperpolarized) and less likely to fire. They also block calcium channels in the nerve terminal, and because calcium entry triggers the release of neurotransmitter, less is released onto the next cell. Figure 5.1 shows these steps.
Quieting nerve cells has different results in different parts of the nervous system. Dhaliwal and Gupta (2023) list analgesia (pain relief), euphoria, dependence, respiratory depression, constricted pupils (miosis) and slowed gut movement among the effects of mu-receptor activation. In pain pathways the receptor reduces the transmission of pain signals; in reward circuits it produces euphoria, which Lesson 8 links to dopamine and learning; and in the brainstem it slows and weakens breathing. Because every opioid in this lesson acts on the same receptor, a drug that relieves pain will also slow breathing as the amount increases. 3-D Model 5.1 lets you step through two of these effects at the level of nerve cells, the extra release of dopamine in a reward circuit and the slowing of the breathing rhythm, and shows how naloxone, which Section 4 explains, reverses both.
Why some opioids are dangerous in amounts too small to see depends on how strongly and how completely each drug activates the receptor, which the next part takes up.
2.3 Agonists, Partial Agonists and Antagonists at the Mu Receptor
Lesson 3 introduced three kinds of drug action at a receptor: a drug can switch it fully on, switch it partly on, or occupy it without switching it on. All three occur among the opioids, and the differences explain both the dangers of the unregulated supply and the action of naloxone.
2.3.1 Full Agonists
A full agonist binds the receptor and produces the largest response the receptor can give. Morphine, the active metabolites of heroin, fentanyl, carfentanil and the nitazenes all act as mu-receptor agonists, and in laboratory assays several nitazenes exceeded fentanyl in both potency and efficacy (Vandeputte et al., 2021). With a full agonist, increasing the amount keeps increasing the effect on breathing until breathing stops.
2.3.2 Partial Agonists and Antagonists
A partial agonist binds the receptor but produces a smaller maximum response, even when every receptor is occupied. Buprenorphine is an opioid partial agonist, and HSCI 402 develops its use in the treatment of opioid use disorder. An antagonist binds the receptor and produces no response of its own, and while it occupies the receptor it prevents agonists from acting. Naloxone is an opioid antagonist, and its ability to push agonists off the mu receptor is the basis of overdose reversal, which Section 4 explains in detail. 3-D Model 5.2 shows the mu-opioid receptor from its measured atomic structures, with fentanyl and morphine in the binding pocket, naloxone in the same pocket of the inactive receptor, and the change in the receptor's shape that lets it switch on its G protein.
2.3.3 Tolerance
Repeated exposure to an opioid changes the nervous system so that the same amount produces a smaller effect, a change called tolerance that Lesson 3 introduced and Lesson 8 develops as neuroadaptation. A person who uses opioids regularly can survive amounts that would stop the breathing of someone without tolerance, and when tolerance fades during a period of not using, the amount they once tolerated becomes dangerous. Section 4 returns to this point.
With these categories in place, the opioids that dominate the Canadian supply can be compared directly, and the next part does so.
3.1 Five Opioids Compared
Five opioids recur in Canadian surveillance reports: morphine, heroin, fentanyl, carfentanil and the nitazenes. They share a receptor but differ in origin, potency, timing and presence in the unregulated supply. The tabs below profile each one.
Morphine is the reference opioid against which the potency of others is usually expressed, and it relieves pain mainly by binding to the mu-opioid receptor. After intravenous administration its terminal half-life is typically about 2 hours, and when it is swallowed less than 40 percent reaches the circulation because of first-pass metabolism in the liver, a process introduced in Lesson 3 (Murphy et al., 2025).
Heroin (diacetylmorphine) is a semi-synthetic opioid made from morphine. In the body it is rapidly broken down into 6-monoacetylmorphine and then morphine (Rook et al., 2006). In a 1981 trial among 166 patients with cancer who had pain after surgery, intramuscular heroin was about twice as potent as morphine (95 percent confidence limits 1.6 to 2.6 times), reached its peak analgesic effect earlier (about 1.2 hours compared with 1.5 hours), and produced effects that were less sustained (Kaiko et al., 1981). Section 2 describes how fentanyl displaced heroin in the unregulated supply.
Fentanyl is a synthetic opioid that was first produced in 1960 and approved for medical use in the United States in 1968. It is typically 50 to 100 times more potent than morphine, it has a half-life of 3 to 7 hours, and the liver metabolizes it mainly through the enzyme CYP3A4 (Ramos-Matos et al., 2023; United States Centers for Disease Control and Prevention [CDC], 2025). Its effects begin quickly: the United States prescribing information for fentanyl citrate injection, revised in June 2026, states that the onset of action is almost immediate when the drug is given intravenously, although the maximal effect may not be reached for several minutes, and that onset after an intramuscular injection takes seven to eight minutes (Hospira, 2026). Illicitly manufactured fentanyl is produced for the unregulated market (CDC, 2025). Among people who died of unregulated drug toxicity in British Columbia in 2025 and underwent expedited toxicology testing, 69 percent had fentanyl in their systems (BC Coroners Service, 2026). Table 5.3 in Section 2 gives a different figure for 2025 because it draws on the Public Health Agency of Canada’s count of apparent opioid toxicity deaths, which uses a different definition.
Carfentanil is a fentanyl analogue used as a tranquilizer for elephants and other large mammals and is not approved for use in humans. When the United States Drug Enforcement Administration issued a public warning in September 2016, it described carfentanil as 10,000 times more potent than morphine and 100 times more potent than fentanyl (United States Drug Enforcement Administration [DEA], 2016). It has appeared in Canadian samples, including a sample seized by law enforcement in Alberta that also contained fentanyl, para-fluorofentanyl, medetomidine and caffeine, and a sample checked in Winnipeg between September 2025 and April 2026 (CCSA, 2026).
Nitazenes are synthetic opioids from a chemical class called benzimidazole opioids. They were developed about 60 years before 2022 as possible pain medicines and had not been approved for clinical use as of 2022; they were first identified in the Canadian unregulated supply in 2019, and some are estimated to be several times more potent than fentanyl (CCSA, 2022). Laboratory work published in 2021 found that a metabolite of isotonitazene, the member most often encountered at the time, is unexpectedly potent (Vandeputte et al., 2021), and a systematic review of fatal cases reported blood concentrations consistent with a potency similar to that of fentanyl for the analogues it examined (Montanari et al., 2022). Because the review drew on a small number of published case reports, its authors advised caution in interpreting these results, so evidence on how potent nitazenes are in people is limited and research is evolving. Fentanyl test strips cannot detect nitazenes (CCSA, 2022).
The profiles show that the opioids differ most of all in potency. Fentanyl, carfentanil and some nitazenes act in amounts far smaller than morphine or heroin, and the final part of this section explains what that means and why it matters for safety.
3.2 Potency and Why Small Amounts Matter
Lesson 3 defined potency as the amount of a drug needed to produce a given effect: a more potent drug produces the effect at a smaller mass. Potency differs from efficacy, the largest effect a drug can produce however much is given. Fentanyl and morphine are both full agonists, so at sufficient amounts both can stop breathing; fentanyl reaches that point at a much smaller mass. This part shows how relative potency is calculated and why it matters in an unregulated market.
3.2.1 Calculating Relative Potency
Relative potency compares two drugs by the masses that produce the same effect. Equation 5.1 expresses it as a simple ratio.
Worked Example 5.1 applies the equation to the figures in Table 5.2, using a pile of grains in place of real amounts so that the comparison involves no doses.
Table 5.2. Potency of four opioids relative to morphine, with the source of each figure; values are approximate and depend on the route, the effect measured and the population studied.
| Opioid | Potency relative to morphine | Source and context |
|---|---|---|
| Morphine | 1 (reference) | Reference drug |
| Heroin | About 2 (95 percent limits 1.6 to 2.6) | Kaiko et al. (1981), intramuscular, postoperative pain in patients with cancer |
| Fentanyl | 50 to 100 | CDC (2025); Ramos-Matos et al. (2023) |
| Carfentanil | About 10,000 | DEA (2016) public warning |
| Nitazenes | Varies by analogue; some similar to fentanyl, some estimated several times more potent than fentanyl | CCSA (2022); Montanari et al. (2022); Vandeputte et al. (2021) |
Imagine that a pile of 10,000 grains of morphine produces a particular effect. Rearranging Equation 5.1, the mass of drug B that produces the same effect is the mass of morphine divided by drug B's relative potency.
Heroin: 10,000 ÷ 2 = 5,000 grains. Fentanyl: 10,000 ÷ 100 = 100 grains at the upper potency figure, and 10,000 ÷ 50 = 200 grains at the lower figure. Carfentanil: 10,000 ÷ 10,000 = 1 grain.
Comparing fentanyl with heroin directly, fentanyl is 50 ÷ 2 = 25 to 100 ÷ 2 = 50 times more potent by mass.
3.2.2 Why Potency Matters in an Unregulated Supply
In a regulated pharmacy, a fentanyl product contains a measured amount, and prescribers adjust for its potency. The danger arises when a highly potent drug is produced and mixed without measurement or labelling, because when the active drug makes up only a tiny fraction of a product's mass, an error that would be trivial for morphine becomes a large change in the amount of opioid a person takes. As a hypothetical illustration, if a batch is meant to contain one part fentanyl in every hundred parts of powder but uneven mixing puts three parts in one portion, that portion carries three times the intended amount of opioid while looking identical. Ciccarone (2019) argued that rapid changes in potency, purity and the mixture of heroin, fentanyl and fentanyl analogues may be even more dangerous than fentanyl's potency itself. Potent drugs are also easy to conceal and transport in small volumes, a point that Section 2 and Lesson 11 develop.
Interactive 5.1 lets you compare any two of the opioids in Table 5.2 and see how many grains of each would match the effect of the reference pile.
Use Interactive 5.1 to compare carfentanil with fentanyl. If a hypothetical batch contained carfentanil in place of fentanyl at the same mass, by roughly what factor would its potency by mass change, and why does the comparison say nothing about which drug has the larger maximum effect? Suggested answer: the batch would be about 100 to 200 times as potent, using Table 5.2; both are full agonists, so either can produce an effect large enough to stop breathing.
Summary and Transition
All opioids act on a receptor system that the body uses for its own peptides. Activating the mu-opioid receptor quiets nerve cells, producing pain relief, euphoria and, as the amount rises, sedation and slowed breathing. Morphine, heroin, fentanyl, carfentanil and the nitazenes share this mechanism and differ mainly in potency and timing: the effect of a pile of 10,000 grains of morphine can be matched by 100 to 200 grains of fentanyl or a single grain of carfentanil. In an unregulated market, that potency turns small mixing errors into large changes in the dose of opioid. The opioids also differ in how long their effects last, from about 2 hours for morphine's half-life to 3 to 7 hours for fentanyl's, a difference that matters in Section 4 because naloxone can wear off before an opioid does. Section 2 traces how fentanyl and its analogues came to dominate the Canadian unregulated supply and how public health agencies monitor what that supply contains.
Key Takeaways
- 1.1 An opiate is a compound found naturally in the opium poppy, such as morphine and codeine, while an opioid is any substance that acts on opioid receptors. Opioid drugs fall into four families: natural opiates, semi-synthetic opioids such as heroin, synthetic opioids such as fentanyl and carfentanil, and novel synthetic opioids such as the nitazenes. As of September 2026, Schedule I of the Controlled Drugs and Substances Act lists the opium poppy and its derivatives, fentanyl and its analogues, and a group of benzimidazoles that includes etonitazene, while morphine and fentanyl remain prescription medicines.
- 2.1 Opioid drugs act on a receptor system that the body uses for its own peptides. Pert and Snyder demonstrated a specific opiate receptor in 1973, and Hughes, Kosterlitz and colleagues identified the enkephalins in 1975. The four main receptor types are mu, delta, kappa and nociceptin, with beta-endorphin and the endomorphins, the enkephalins, the dynorphins and nociceptin as their main natural partners, and the mu receptor is the main target of the opioids in the Canadian supply.
- 2.2 Activating the mu-opioid receptor switches on inhibitory G proteins that block calcium channels, open potassium channels and lower cyclic AMP, so the nerve cell becomes quieter and releases less neurotransmitter. In pain pathways this relieves pain, in reward circuits it produces euphoria, and in the brainstem it slows breathing, so a drug that relieves pain will also slow breathing as the amount rises. Other effects include constricted pupils and slowed gut movement.
- 2.3 A full agonist such as morphine, fentanyl, carfentanil or a nitazene produces the largest response the receptor can give, so increasing the amount keeps deepening the effect on breathing. A partial agonist such as buprenorphine produces a smaller maximum response, and an antagonist such as naloxone occupies the receptor without activating it. Tolerance means that repeated exposure makes the same amount produce a smaller effect, and when tolerance fades, an amount once tolerated becomes dangerous.
- 3.1 Morphine, heroin, fentanyl, carfentanil and the nitazenes share the mu receptor but differ in origin, potency, timing and presence in the unregulated supply. Heroin is about twice as potent as morphine, fentanyl 50 to 100 times, and carfentanil was described as about 10,000 times, while some nitazenes are estimated to be several times more potent than fentanyl. Their effects also last for different times, from a half-life of about 2 hours for morphine to 3 to 7 hours for fentanyl.
- 3.2 Relative potency is the mass of a reference drug divided by the mass of another drug that produces the same effect, so an effect produced by 10,000 grains of morphine is matched by 5,000 grains of heroin, 100 to 200 grains of fentanyl or a single grain of carfentanil. Potency concerns the mass needed for an effect, while efficacy is the largest effect a drug can produce. In an unregulated market, high potency turns small, invisible mixing errors into large changes in the dose of opioid.
Reflection
A friend says: “Fentanyl is 50 to 100 times stronger than morphine, so it must cause 50 to 100 times more harm.” In Worked Example 5.1, an effect produced by a pile of 10,000 grains of morphine is matched by about 5,000 grains of heroin, 100 to 200 grains of fentanyl and 1 grain of carfentanil. Using the ideas of potency and efficacy and the action of opioids at the mu-opioid receptor, write a short explanation (150 to 200 words) of what your friend's statement gets right, what it gets wrong, and why fentanyl's potency becomes dangerous in an unregulated supply.
Minimum 20 characters required.
Question 1: Which statement best describes the difference between an opiate and an opioid?
Question 2: When an opioid activates a mu-opioid receptor on a nerve terminal, which change follows?
Question 3: In Worked Example 5.1, a pile of 10,000 grains of morphine produces a given effect. Using Equation 5.1 and the figure of about 2 for heroin's potency relative to morphine, about how many grains of heroin produce the same effect?
Question 4: Fentanyl and morphine are both full agonists at the mu-opioid receptor. Which statement about the two drugs is correct?
How the Unregulated Supply Became Toxic: Waves, Fentanyl and Monitoring
Content note. This section reports counts of drug toxicity deaths in British Columbia and across Canada. If you would like support, the 9-8-8 Suicide Crisis Helpline is available by call or text at 9-8-8, the National Overdose Response Service can be reached at 1-888-688-6677, and the Hope for Wellness Help Line for Indigenous people can be reached at 1-855-242-3310.
Introduction
Section 1 showed that potency becomes dangerous when drugs are made and mixed without measurement or labels. This section asks how that situation arose. Within a few years, British Columbia's unregulated opioid supply changed from one dominated by heroin to one dominated by illicitly manufactured fentanyl, and it has since moved toward fentanyl analogues mixed with sedatives. Ciccarone (2019) described these changes as waves; a review by Ciccarone (2021) and a RAND report by Pardo and colleagues (2019) explain them mainly through the decisions of suppliers; and Canadian agencies track them with several imperfect monitoring systems. Because Canadian agencies use different words and definitions for these deaths, the section also explains how they are named and counted before it turns to the monitoring systems.
Learning Objectives
- 4.1 Explain Ciccarone's triple wave model of the opioid overdose crisis and the later wave involving stimulants, and describe how Canadian surveillance data from 2016 onward fit and depart from it.
- 4.2 Describe, with dated figures, how illicitly manufactured fentanyl came to dominate the unregulated opioid supply in British Columbia between 2012 and 2018.
- 4.3 Explain the supply-side account of the shift to fentanyl given by Ciccarone (2019, 2021) and by Pardo and colleagues (2019).
- 4.4 Describe, with dated Canadian figures, the later shift toward fentanyl analogues, nitazenes and stimulant involvement, and interpret national surveillance data from 2016 to 2025.
- 5.1 Explain why Canadian agencies speak of overdose, drug toxicity and poisoning deaths, and why counts from different agencies for the same year can differ.
- 5.2 Compare the main sources that monitor the composition of the unregulated supply (seized-drug analysis, drug checking, post-mortem toxicology, wastewater testing and sentinel networks) and state a strength and a limit of each.
4.1 Waves of the Overdose Crisis
One account of how the opioid crisis developed comes from the United States, where national mortality data allow deaths to be sorted by type of opioid. Daniel Ciccarone (2019) described a triple wave epidemic, in which deaths from three classes of opioids rose one after another, each wave cresting on top of the one before. This part describes the model, its later extension, and how Canadian data compare.
4.1.1 The Triple Wave Model
In Ciccarone's account, the first wave involved prescription opioid pills. Opioid prescriptions in the United States tripled starting in the 1990s and peaked around 2011, and deaths involving opioid pills rose steadily from 2000. The second wave involved heroin: heroin deaths began rising clearly in 2007 and accelerated from 2011, as a growing number of people moved from pills to cheaper, more available heroin. Ciccarone notes that the late-2010 reformulation of OxyContin, a brand of extended-release oxycodone, to make it harder to crush and inject may have pushed a small share of people toward heroin. The third wave involved illicitly manufactured fentanyl and its analogues, which climbed slowly at first and dramatically after 2013 (Ciccarone, 2019). Figure 5.2 sketches the shape of the model.
The waves were linked. Many people who developed opioid dependence through pills later moved to heroin, and in the regions where heroin was most common, heroin became contaminated with or replaced by fentanyl (Ciccarone, 2019). In a review of stimulant use, Ciccarone and Shoptaw (2022) later described a fourth wave of high mortality involving methamphetamine and cocaine, which in many deaths occur together with opioids. Lesson 6 introduces the stimulants, and HSCI 402 develops prescription opioids and overdose mortality in depth.
4.1.2 How Canada's Experience Compares
Canada's national surveillance of opioid deaths began in 2016, during the third wave (PHAC, 2026), and shows the same movement from pharmaceutical to unregulated opioids. In 2018, 28 percent of apparent opioid toxicity deaths in Canada involved only pharmaceutical opioids and 62 percent involved only non-pharmaceutical opioids; by 2025 those shares were 15 percent and 75 percent (PHAC, 2026). The fourth wave is also visible: the share of opioid deaths that also involved a stimulant rose from 57 percent in 2018 to 71 percent in 2025 nationally, and reached 80 percent in British Columbia in 2024 and 2025 (PHAC, 2026). Case 5.1 describes the moment when British Columbia's government recognized that its own third wave had become an emergency.
On 14 April 2016, British Columbia's provincial health officer, Dr. Perry Kendall, used his powers under the Public Health Act to declare a public health emergency in response to the rise in drug overdoses and deaths. The province had recorded 474 apparent illicit drug overdose deaths in 2015, a 30 percent increase over the 365 deaths in 2014, and 76 deaths in January 2016 alone. Fentanyl had been detected in about 5 percent of illicit drug overdose deaths in 2012, 15 percent in 2013, 25 percent in 2014 and about 31 percent in 2015. Until then, overdoses were reported only when someone died; the declaration allowed medical health officers to collect real-time information on overdoses (BC Ministry of Health, 2016).
The figures in Case 5.1 already show the fentanyl wave arriving in British Columbia. The next three parts follow that change through to 2026 and ask why it happened.
4.2 The Shift to Illicitly Manufactured Fentanyl
Between 2012 and 2018, fentanyl moved from a rare finding in British Columbia's drug deaths to a near-universal one. This part sets out the timeline from two sources; the next two parts examine the explanation given for it in a review and a research report, and the more recent move toward fentanyl analogues and mixed supplies.
Table 5.3 combines the figures from the 2016 emergency declaration with later surveillance data from the Public Health Agency of Canada. The two sources use different definitions (the first counts all illicit drug overdose deaths, the second counts apparent opioid toxicity deaths), so the table shows the direction and pace of change and should not be read as a single consistent series.
Table 5.3. Percentage of drug deaths in British Columbia in which fentanyl was detected, 2012 to 2025, from two sources with different definitions.
| Year | Fentanyl detected | Fentanyl analogues detected | Source and definition |
|---|---|---|---|
| 2012 | About 5% | Not reported | BC Ministry of Health (2016); illicit drug overdose deaths |
| 2013 | About 15% | Not reported | |
| 2014 | About 25% | Not reported | |
| 2015 | About 31% | Not reported | |
| 2016 | 80% | 3% | PHAC (2026); apparent opioid toxicity deaths in BC |
| 2018 | 94% | 5% | |
| 2021 | 92% | 23% | |
| 2023 | 87% | 49% | |
| 2025 | 75% | 61% |
In six years, fentanyl went from about one death in twenty to more than nine in ten. The number of deaths rose with it: the Public Health Agency of Canada counted 807 apparent opioid toxicity deaths in British Columbia in 2016 and 2,293 in 2023, the highest annual count for the province from 2016 to 2025 in the data published in September 2026 (PHAC, 2026).
4.3 Why Fentanyl Replaced Heroin
A 2021 review by Ciccarone described fentanyl's rise as driven more by supply than by demand (Ciccarone, 2021), and his earlier paper set out two features of the shift that support that account. In the United States, fentanyl deaths clustered in the regions where powder heroin was common, and Ciccarone (2019) argued that such sharp regional differences fit a supply-side event, since a change driven by demand would have spread more evenly. Ethnographic research also found that many people who used heroin experienced fentanyl as an unexpected change and could not reliably choose or avoid it, because it was sold as heroin or as counterfeit pills (Ciccarone, 2019). The box below summarizes the economic reasoning.
The supply-side account of fentanyl
A 2019 RAND report led by Bryce Pardo concluded that the transition to fentanyl was driven by supplier decisions, and the authors did not find that it was driven by demand from people who use drugs. For suppliers, synthetic opioids were largely a strategic device to lower costs or avoid drug laws, helped by synthesis methods shared online and weak regulation of chemical production in China. The authors found that once fentanyl gains a foothold it appears capable of sweeping through a market in a few years, and that up to 2019 its spread had been episodically fast, with what they called ratchet-like persistence. The report also noted that problems in parts of Canada were as severe as in the eastern United States, despite large differences in drug policy (Pardo et al., 2019).
Potency makes the product easy to hide. Ciccarone (2019) noted that 668 kilograms of fentanyl were seized in the United States in 2016, a small fraction of the estimated 11 metric tons of cocaine seized at the southwest border alone that year, and that the 2.6 metric tons he estimated were distributed in the United States that year could fit in about ten industrial drums. Lesson 11 develops this point as the iron law of prohibition.
Demand still plays a role: Ciccarone (2019) emphasized that demand for opioid pills created a population dependent on opioids, which later sustained demand for heroin and then for whatever was sold as heroin. His 2021 review added that demand for fentanyl itself has been described as polarized, with some people who use drugs seeking it out and others trying hard to avoid it (Ciccarone, 2021). Research on these markets is evolving. Once fentanyl was established, the supply did not stand still, as the next part shows.
4.4 Fentanyl Analogues, Nitazenes and Mixed Supplies
The supply has kept changing since fentanyl became dominant. Nationally, the share of apparent opioid toxicity deaths involving a fentanyl analogue rose from 10 percent in 2018 to 60 percent in 2025, while the share involving fentanyl itself fell from 86 percent in 2021 to 57 percent in 2025; in January to March 2026, fentanyl analogues were involved in 70 percent of deaths and fentanyl in 36 percent (PHAC, 2026). In British Columbia, the BC Coroners Service's expedited toxicology for 2025 found fentanyl in 69 percent of people who died of unregulated drug toxicity and fluorofentanyl, a fentanyl analogue, in 54 percent; cocaine was found in 53 percent and methamphetamine in 52 percent (BC Coroners Service, 2026). Nitazenes were first identified in the Canadian supply in 2019. Health Canada's Drug Analysis Service found a nitazene in 0.8 percent of all samples it analyzed in 2021 (872 of 108,374), more than three times the share of 0.2 percent in 2020 (248 of 101,809) (CCSA, 2022). Section 3 describes the sedatives that Canadian monitoring has found alongside these opioids since about 2019.
The way people use the supply has also changed. In 2025, smoking was the most common mode of consumption among people who died of unregulated drug toxicity in British Columbia (65 percent), followed by nasal insufflation (11 percent), injection (9 percent) and oral use (4 percent) (BC Coroners Service, 2026). Lesson 3 explained how routes of administration shape the speed and intensity of drug effects.
Interactive 5.2 draws on the Public Health Agency of Canada's surveillance data, updated in September 2026, for Canada and British Columbia. Use it to follow the number of deaths, the crude death rate, and the share of deaths involving fentanyl, fentanyl analogues and stimulants from 2016 to 2025.
Three patterns stand out. Deaths rose sharply in 2020, the first year of the COVID-19 pandemic, and in the data published in September 2026 they were highest in 2023. They then fell by 29 percent nationally and 19 percent in British Columbia between 2023 and 2025. Throughout, the share of deaths involving fentanyl analogues and stimulants grew. The data do not by themselves explain why deaths fell, a question that HSCI 402 takes up with the methods of policy evaluation.
5.1 Naming and Counting Drug Deaths
The figures in this section come from agencies that use different words and definitions for the deaths they count. Before turning to how the supply itself is monitored, it helps to be clear about how these deaths are named, which the first box below explains.
Overdose, drug toxicity or poisoning?
The BC Coroners Service reports unregulated drug toxicity deaths, and the Public Health Agency of Canada reports apparent opioid toxicity deaths. Everyday speech uses overdose. All three describe deaths in which a drug, or a combination of drugs, overwhelmed the body. The word overdose can suggest that a person knowingly took too much of a drug whose strength they understood. Some agencies, researchers and advocates prefer toxicity or poisoning because in the unregulated supply people often cannot know what a substance contains: Canadian reports describe exposure to xylazine and nonmedical benzodiazepines as mostly unintended (CCSA, 2023; CCSA, 2025). This course uses overdose death and drug toxicity death as equivalent terms and keeps each agency's own term when reporting its figures.
Different sources can also give different numbers for what looks like the same quantity. The second box explains why, using British Columbia's figures for 2025.
One province, one year, two counts
In February 2026, the BC Coroners Service reported 1,826 unregulated drug toxicity deaths in British Columbia in 2025, 21 percent fewer than the 2,315 deaths it now counted for 2024, and described these figures as preliminary (BC Coroners Service, 2026). In September 2026, the Public Health Agency of Canada reported 1,855 apparent opioid toxicity deaths in British Columbia for 2025 (PHAC, 2026). The two figures were reported seven months apart, and counts rise as toxicology results arrive and investigations close. Definitions also matter: PHAC notes that from 2025 its figure for British Columbia includes deaths related to all unregulated drugs, so its national counts from 2025 onward are not defined in exactly the same way as those for earlier years, and comparisons across those years (including Interactive 5.2) span that change. When you cite a figure, give the agency, its definition and the date it was reported.
The changes described in this section were detected and measured by monitoring systems that are themselves limited. The final part of this section examines how those systems work.
5.2 How the Composition of the Supply Is Monitored
Unregulated drugs carry no ingredient list, so agencies infer what the supply contains from sources that observe it at different points: when drugs are seized, when they are checked before use, after they pass through the body, and after a death. Each source has blind spots.
5.2.1 Five Sources of Information
Table 5.4 compares the five main sources described in Canadian reports. HSCI 402 develops drug checking as a harm reduction service; the focus here is on what each source reveals about the supply.
Table 5.4. Sources that monitor the composition of the unregulated drug supply in Canada, with a strength and a limit of each (compiled from CCSA, 2022, 2023, 2025 and 2026, and BC Coroners Service, 2026).
| Source | What it observes | A strength | A limit |
|---|---|---|---|
| Health Canada's Drug Analysis Service | Laboratory analysis of drugs seized and submitted by law enforcement | The most comprehensive national source, with large sample numbers | A lagging indicator because of delays in submission and reporting, and not necessarily representative of what circulates |
| Community drug checking services | Samples brought by people who use drugs, tested on site and sometimes sent for confirmatory testing | Timely, and linked to what the person expected to buy | Portable spectrometers miss substances present in small amounts, and test strips detect only the substance they target |
| Coroner and medical examiner toxicology | Substances detected in the blood of people who died | Links substances directly to deaths | Detects only substances included in the testing panel, and results are preliminary for months |
| Wastewater surveillance | Drugs and their breakdown products in community sewage | Anonymous and community-wide; Health Canada's program screens for more than 550 drugs and metabolites | Limited geographic coverage, and it cannot link a substance to a person or an outcome |
| Sentinel networks such as CCENDU | Reports from local partners, including clinicians, researchers, police and people with lived experience | Detects new trends and harms quickly and adds context | Reports may not represent a whole province or territory |
Figure 5.3 arranges these sources along the path that a drug follows from seizure or purchase to use and, in the worst case, to a death. Sources early in the path tend to be faster, and sources late in the path tend to give firmer links to harm.
5.2.2 How the Tools Work and Where They Fall Short
The technology behind each source determines what it can find. Open each item in the accordion below to read about it.
Health Canada's Drug Analysis Service identifies the contents of samples submitted by police and border agencies across Canada. Its data show national trends, such as the rise of nitazenes from 248 samples in 2020 to 872 in 2021 (CCSA, 2022). Because the samples come from enforcement, they reflect police activity as well as the market, and delays in submitting samples and reporting results make the data a lagging indicator (CCSA, 2026). Substances that are not controlled, such as xylazine, have not been systematically tested and reported (CCSA, 2023).
Many community services use a Fourier-transform infrared (FTIR) spectrometer, which identifies a sample's main components by how they absorb infrared light. It is fast but misses substances present in small amounts; for medetomidine, it is not sensitive below about 5 percent of a sample (CCSA, 2026). Immunoassay test strips detect a single target substance at low levels, so a fentanyl test strip cannot detect a nitazene (CCSA, 2022). Some services send a share of samples to laboratories with mass spectrometry for confirmatory testing; in British Columbia, results from this secondary testing can take about a week (CCSA, 2026).
The BC Coroners Service uses expedited testing to report trends quickly and revises its figures as full results arrive (BC Coroners Service, 2026). Toxicology finds only what the laboratory tests for: in 2022 nitazenes were not routinely included in post-mortem or urine toxicology (CCSA, 2022), and in 2026 medetomidine was not part of the broad-scope post-mortem test used in Nova Scotia (CCSA, 2026).
Health Canada's National Wastewater Drug Surveillance initiative measures drugs and their metabolites in samples of community sewage. It screens for more than 550 substances, but its geographic coverage is limited (CCSA, 2026).
The Canadian Community Epidemiology Network on Drug Use (CCENDU), co-ordinated by the Canadian Centre on Substance Use and Addiction, had 13 sites in all ten provinces and one territory in 2026, bringing together about 81 organizations and more than 200 members, including people with lived and living experience of substance use (CCSA, 2026). Health Canada's Canadian Drug and Substance Watch combines Drug Analysis Service data with wastewater results and monitoring of online forums (CCSA, 2025).
Decide which source in Table 5.4 would best answer each question, and name one limit. (a) Has a new nitazene appeared in samples sold as fentanyl in Toronto in recent weeks? (b) Was medetomidine present in people who died in a province last year? (c) Is a substance being consumed across a whole city? (d) Which provinces have the highest share of seized fentanyl samples containing a veterinary tranquilizer? Suggested answers: (a) drug checking, which can miss nitazenes; (b) post-mortem toxicology, if medetomidine was in the panel; (c) wastewater, which cannot link use to people or outcomes; (d) the Drug Analysis Service, which lags behind the market.
Summary and Transition
Ciccarone's triple wave model describes a crisis that moved from prescription pills to heroin to illicitly manufactured fentanyl, followed by a fourth wave involving stimulants. Canadian surveillance began during the third wave and shows fentanyl rising in British Columbia from about 5 percent of drug deaths in 2012 to between 87 and 94 percent of opioid deaths in each year from 2017 to 2022, followed by a shift toward fentanyl analogues such as fluorofentanyl. A 2021 review and a 2019 RAND report attribute the change mainly to suppliers seeking cheaper and more concealable products, although demand was mixed and research on these markets is evolving. Knowledge of the supply comes from seized-drug analysis, drug checking, post-mortem toxicology, wastewater testing and sentinel networks, each with blind spots. Since about 2019, these systems have also detected sedatives that are not opioids mixed into the opioid supply, which Section 3 examines.
Key Takeaways
- 4.1 Ciccarone's triple wave model describes a United States crisis in which deaths from prescription opioid pills rose from 2000, heroin deaths rose clearly from 2007, and deaths from illicitly manufactured fentanyl climbed dramatically after 2013; Ciccarone and Shoptaw later added a fourth wave involving methamphetamine and cocaine. Canadian national surveillance began in 2016, during the third wave, and shows the same move from pharmaceutical to non-pharmaceutical opioids, with a stimulant involved in 71 percent of opioid deaths nationally in 2025.
- 4.2 In British Columbia, fentanyl was detected in about 5 percent of illicit drug overdose deaths in 2012 and about 31 percent in 2015, and in 80 to 94 percent of apparent opioid toxicity deaths from 2016 to 2018. The province declared a public health emergency on 14 April 2016, and annual deaths rose from 807 in 2016 to 2,293 in 2023. The two sources behind these figures use different definitions, so together they show direction and pace rather than a single series.
- 4.3 A 2021 review and a 2019 RAND report attribute the shift to fentanyl mainly to supplier decisions: fentanyl deaths clustered where powder heroin was sold, buyers often could not choose or avoid it, and Pardo and colleagues described synthetic opioids as a strategic device to lower costs and avoid drug laws. Fentanyl's potency makes it easy to conceal, and up to 2019, once established, it had shown ratchet-like persistence. Demand still matters, because dependence created by opioid pills sustained the market for heroin and for whatever was sold as heroin.
- 4.4 Nationally, the share of apparent opioid toxicity deaths involving a fentanyl analogue rose from 10 percent in 2018 to 60 percent in 2025, and in British Columbia in 2025 fluorofentanyl was found in 54 percent of people who died of unregulated drug toxicity. Nitazenes were first identified in the Canadian supply in 2019, and in British Columbia in 2025 smoking was the most common mode of consumption among people who died. In the data published in September 2026, deaths were highest in 2023 and fell by 29 percent nationally and 19 percent in British Columbia by 2025, while the shares involving analogues and stimulants kept growing.
- 5.1 The BC Coroners Service reports unregulated drug toxicity deaths, the Public Health Agency of Canada reports apparent opioid toxicity deaths, and everyday speech uses overdose; some prefer toxicity or poisoning because people often cannot know what an unregulated drug contains. Counts for the same year can differ because they are reported at different times, rise as toxicology results arrive and use different definitions, so a cited figure should name the agency, its definition and the date it was reported.
- 5.2 Seized-drug analysis by Health Canada's Drug Analysis Service, community drug checking, post-mortem toxicology, wastewater testing and sentinel networks such as CCENDU each observe the supply at a different point. Seized-drug data are comprehensive but lag behind the market, drug checking is timely but misses small amounts and untargeted substances, toxicology links substances to deaths but finds only what its panel includes, wastewater testing is community-wide but cannot link use to people, and sentinel reports detect trends quickly but may not represent a whole province.
Reflection
Fentanyl was detected in about 5 percent of British Columbia's illicit drug overdose deaths in 2012, 15 percent in 2013, 25 percent in 2014 and about 31 percent in 2015 (BC Ministry of Health, 2016), and in 80 to 94 percent of the province's apparent opioid toxicity deaths from 2016 to 2018 (PHAC, 2026). Pardo and colleagues (2019) concluded that supplier decisions drove the transition to fentanyl. In 150 to 250 words, (a) explain the supply-side account in your own words, (b) name one piece of evidence that supports it, and (c) identify one source you would use to detect the next change in the supply and one limit of that source.
Minimum 20 characters required.
Question 1: In Ciccarone's (2019) triple wave model of the United States opioid crisis, what was the third wave?
Question 2: According to British Columbia's 2016 public health emergency announcement, in roughly what share of illicit drug overdose deaths was fentanyl detected in 2012 and in 2015?
Question 3: Which observation did Ciccarone (2019) use to argue that the shift to fentanyl was driven mainly by suppliers?
Question 4: A drug checking service relies on a portable FTIR spectrometer and fentanyl test strips. Which substance in a sample sold as fentanyl is it most likely to miss?
Sedative Adulterants: Xylazine, Medetomidine and Nonmedical Benzodiazepines
Content note. This section discusses drug poisonings, wounds and drug toxicity deaths. If you would like support, the 9-8-8 Suicide Crisis Helpline is available by call or text at 9-8-8, the National Overdose Response Service can be reached at 1-888-688-6677, and the Hope for Wellness Help Line for Indigenous people can be reached at 1-855-242-3310.
Introduction
Section 2 ended with a supply dominated by fentanyl and its analogues. Since about 2019, Canadian monitoring systems have found that many samples sold as opioids also contain sedatives from two other drug classes: veterinary tranquilizers that act on the body's adrenaline system, and benzodiazepine-type drugs, many of them not approved as medicines for the Canadian market. These substances are not opioids, so naloxone does not reverse their effects, and they bring harms of their own, from deep sedation and slow heart rate to wounds and severe withdrawal. This section explains what these sedatives are, how they act, how quickly they have changed, and why their presence changes what an overdose looks like.
Learning Objectives
- 6.1 Define an adulterant, explain why, by 2025, sedatives that are not opioids appeared in much of the Canadian unregulated opioid supply, and name the three receptor systems involved.
- 6.2 Explain how xylazine acts as an alpha-2 adrenergic agonist, describe its effects on alertness, heart rate and blood pressure, and describe its spread in Canada and the wounds linked to it.
- 6.3 Explain how medetomidine resembles and differs from xylazine, and trace, with dated Canadian data, how it displaced xylazine in the unregulated opioid supply between 2024 and 2026.
- 6.4 Describe nonmedical benzodiazepines such as bromazolam, including how they act and how often they appear in Canadian opioid samples.
- 6.5 Explain why sedative adulterants produce prolonged sedation that naloxone does not reverse, and describe the risks of prolonged sedation and the withdrawal syndromes linked to each class.
6.1 Adulterants and Three Receptor Systems
An adulterant is a substance in a drug product other than the drug the buyer expected, whether it was added deliberately or entered through contamination. In a regulated market, a product's contents are tested and labelled; in the unregulated market there is no quality control, and Canadian reports describe the introduction of new adulterants as constant, rapid and unpredictable (CCSA, 2023). This part introduces the three receptor systems involved and the classes of drug that act on them.
The sedatives found in the opioid supply act on different receptors from the opioids, which is why they respond differently to treatment. Figure 5.4 shows the three systems side by side. Opioids act on the mu-opioid receptor described in Section 1. Xylazine and medetomidine act on alpha-2 adrenergic receptors, which respond to noradrenaline, a chemical messenger of the body's adrenaline system; drugs that activate these receptors damp down that system and cause sedation and lower blood pressure (CCSA, 2026). Benzodiazepine-type drugs act on the GABA-A receptor, the brain's main inhibitory receptor, which Lesson 4 described. Each class can depress the nervous system, so their effects add together, but naloxone acts only on the opioid receptor.
Table 5.5 compares the three groups of sedating adulterants on the features that matter for health. The rest of this section explains each row in turn.
Table 5.5. Sedatives found in the Canadian unregulated opioid supply compared on receptor, main effects, response to naloxone and withdrawal (sources: CCSA, 2023, 2025 and 2026; Ruiz-Colón et al., 2014; Sait & Mudhaffar, 2026).
| Feature | Xylazine | Medetomidine | Nonmedical benzodiazepines |
|---|---|---|---|
| Drug class | Veterinary tranquilizer; alpha-2 adrenergic agonist | Veterinary tranquilizer; alpha-2 adrenergic agonist, about 100 to 200 times more potent than xylazine | Illegally produced or diverted benzodiazepines and related drugs, including bromazolam, not approved for the Canadian market |
| Main effects with opioids | Prolonged sedation; slow heart rate and low blood pressure | Severe, prolonged sedation; slow heart rate; low blood pressure after early high blood pressure | Prolonged sedation and memory loss |
| Reversed by naloxone | No | No; as of 2026, no reversal agent approved for humans | No |
| Distinctive harm | Skin ulcers and wounds with tissue death | Severe withdrawal with high heart rate and blood pressure, described in early reports | Withdrawal that can include seizures |
| First Canadian detection by the Drug Analysis Service | 2019 | 2023 (British Columbia, Ontario and Quebec) | Bromazolam: 2021, British Columbia |
Xylazine was detected in Canada several years before medetomidine, and the next part begins with it.
6.2 Xylazine
Xylazine is a veterinary sedative that has appeared in unregulated opioid supplies in Canada and the United States. This part describes its pharmacology, how common it became in Canada, and the harms linked to it.
6.2.1 Pharmacology and Effects
Xylazine is an alpha-2 adrenergic agonist developed as a sedative for animals (Sait & Mudhaffar, 2026). It is marketed as a veterinary drug for sedation, pain relief and muscle relaxation, and in humans it can cause central nervous system depression, respiratory depression, a slow heart rate (bradycardia), low blood pressure (hypotension) and death (Ruiz-Colón et al., 2014). It is not an opioid, so naloxone does not reverse its effects, although naloxone still reverses the opioid it is mixed with. The result can be prolonged sedation after an opioid overdose has been reversed (CCSA, 2023). In the version current to 30 September 2026, xylazine does not appear in the schedules of Canada's Controlled Drugs and Substances Act, and a 2023 Canadian report noted that, for this reason, its testing and reporting in seized samples has not been systematic (CCSA, 2023).
6.2.2 Xylazine in Canada, 2019 to 2023
Health Canada's Drug Analysis Service first identified xylazine in 2019, and by March 2023 had found it in ten provinces and territories. The share of fentanyl samples that also contained xylazine rose from 1.4 percent in January 2020 to about 12 percent in June 2022, the highest share in the period the report covered, and stood at 9.0 percent in April 2023. Xylazine was rarely found alone: up to 99 percent of xylazine-containing samples analyzed between May 2022 and April 2023 also contained fentanyl. Toronto's Drug Checking Service found xylazine in about 26 percent of samples expected to be fentanyl in June 2022, its highest share up to April 2023, and in 11 percent in April 2023 (CCSA, 2023). In fatal cases, a 2026 systematic review of studies, most of them from the United States, found fentanyl co-detected in 98 to 100 percent of xylazine-positive deaths in several studies (Sait & Mudhaffar, 2026). As of the end of April 2023, no drug toxicity death in Canada had been attributed directly to xylazine, and mortality continued to be driven by unregulated opioids, particularly fentanyl (CCSA, 2023).
6.2.3 Wounds
The harm most specific to xylazine is damage to the skin. Xylazine exposure is associated with skin ulcers and extensive wounds involving tissue death, possibly because of its effects on blood vessels, and these wounds can appear away from injection sites (CCSA, 2023). A 2026 scoping review of published cases described wounds that begin as dark blisters and can progress to deep ulcers needing surgery (Vaile et al., 2026), and a 2026 systematic review of 277 patients found that 9.5 percent required amputation (Call et al., 2026). Both reviews draw on published case reports (259 of the 277 patients in the second were reported in Pennsylvania), so they show what can happen; estimating how often it happens needs larger studies. Wound care is difficult to obtain outside hospitals for many people who use drugs, which Canadian reports identify as a gap in services (CCSA, 2023).
Between 2024 and 2026, xylazine was largely displaced in Canada by a related and more potent tranquilizer. The next part describes that change.
6.3 Medetomidine Displaces Xylazine
Medetomidine spread through the Canadian unregulated opioid supply between 2024 and 2026. The Canadian Centre on Substance Use and Addiction and its CCENDU network devoted a June 2026 report to it, and this part draws mainly on that report (CCSA, 2026).
6.3.1 What Medetomidine Is
Medetomidine is an alpha-2 adrenergic agonist approved as a veterinary tranquilizer for surgery in animals; as of 2026 it was not approved for use in humans. A closely related compound, dexmedetomidine, is approved for sedation in human medicine. Medetomidine's mechanism and effects resemble those of xylazine, but it is about 100 to 200 times more potent. Its adverse effects include severe and prolonged sedation, slow heart rate, low blood pressure (with high blood pressure possible immediately after use), delirium or hallucinations, dizziness and fluctuating consciousness (CCSA, 2026). As of June 2026, wounds of the kind linked to xylazine had not been reported for medetomidine, and its withdrawal was reported to be more severe than xylazine withdrawal, a point taken up in 6.5 Why Sedative Adulterants Complicate Overdose and Withdrawal. A 2025 review found that knowledge of medetomidine as an adulterant remains limited, so research on its effects in people is evolving (Sood, 2025).
6.3.2 How Quickly It Spread
Medetomidine first emerged in British Columbia, Ontario and Quebec in 2023, and between 1 January 2024 and 31 March 2026, 5,325 samples submitted to Health Canada's Drug Analysis Service contained it (CCSA, 2026). Case 5.2 describes the pattern seen by one drug checking service, and Figure 5.5 plots the values reported for Toronto and British Columbia.
Toronto's Drug Checking Service detected medetomidine in 1,462 samples between August 2024 and March 2026, almost all of them expected to be opioids. Medetomidine was found in 12 percent of expected fentanyl samples in August 2024 (20 of 170), a share that rose steadily to 86 percent in February 2026 (82 of 95), the highest month in the report, and stood at 77 percent in March 2026 (104 of 135). Its concentration in expected fentanyl samples also rose, with the median increasing from 0.3 percent of the sample in January 2025 to 1.2 percent in March 2026. Of the 1,226 medetomidine-positive samples for which the report gives this breakdown, 96 percent (1,172) also contained at least one high-potency opioid, such as fentanyl, para-fluorofentanyl, orthomethylfentanyl or the nitazene protodesnitazene (CCSA, 2026).
British Columbia showed the same pattern. Among opioid samples sent for secondary testing by community drug checking services, medetomidine was found in about 5 to 20 percent each month in the first half of 2025, nearly 40 percent by August 2025, 45 percent in November 2025 and nearly 50 percent in January 2026. Over the same period, xylazine fell from about 25 percent of these samples in January 2025 to 2 percent by the end of the year. A two-week pilot of medetomidine test strips in November 2025 found it in 34 percent of samples across the province, with regional values from 15 to 50 percent (CCSA, 2026). The national summary concluded that as medetomidine increased, xylazine decreased, a shift that appears to be associated with fewer new xylazine wounds and more medetomidine-related harms such as cardiac events and severe withdrawal (CCSA, 2026).
6.3.3 What Responders and Clinicians Reported
The reports collected by CCENDU describe toxicity events that are more complex and harder to manage. In Alberta, sedation sometimes lasted up to a week, and responders reported using more naloxone and needing longer monitoring. In British Columbia, 9-1-1 calls for ingestion poisonings reached a one-day high of 1,471 on 22 February 2026, and slow heart rate became a substantial concern in emergency departments, although deaths in the province had not increased and had remained relatively steady since a decline in October 2024 (CCSA, 2026). Medetomidine is also hard to detect: portable FTIR spectrometers miss it below about 5 percent of a sample, test strips cost more than two dollars each, and, as of June 2026, no clinical test was available to confirm exposure in a patient (CCSA, 2026).
The veterinary tranquilizers are one of two sedative classes in the opioid supply. The other, older and in many places more common, is the subject of the next part.
6.4 Nonmedical Benzodiazepines
Benzodiazepines are central nervous system depressants used in medicine to treat anxiety, sleep and seizure disorders; Lesson 4 described how they enhance the action of GABA at the GABA-A receptor and why combining them with opioids suppresses breathing. This part describes the benzodiazepine-type drugs that appear in the unregulated opioid supply.
6.4.1 What Nonmedical Benzodiazepines Are
Nonmedical benzodiazepines are benzodiazepines and benzodiazepine-like substances that are either produced illegally or diverted from legal sources. Some, such as alprazolam and clonazepam, are prescription medicines; others, sometimes called novel or designer benzodiazepines, were developed but not approved for the Canadian market or were newly synthesized (CCSA, 2025). Schedule IV of the Controlled Drugs and Substances Act lists benzodiazepines and their derivatives (Controlled Drugs and Substances Act, 1996). Because designer benzodiazepines resemble prescribed ones, the screening tests used in hospitals often cannot tell them apart, and laboratories need mass spectrometry to identify them (Bazydlo & Larkey, 2025).
6.4.2 Bromazolam and Its Relatives in Canada
Bromazolam is a novel benzodiazepine that has been widely found in the Canadian supply. Health Canada's Drug Analysis Service first detected it in British Columbia in 2021, and it was later found in Alberta, Ontario, Quebec, Saskatchewan, Manitoba, the Northwest Territories, Nova Scotia, Prince Edward Island and Newfoundland and Labrador. In British Columbia's drug checking results, bromazolam overtook etizolam as the most common nonmedical benzodiazepine in expected opioids toward the end of 2022, and in the six months before the report of January 2025 desalkylgidazepam was also among the most common (CCSA, 2025). Nationally, about half of the fentanyl-containing samples analyzed by the Drug Analysis Service in 2023 and 2024 also contained a nonmedical benzodiazepine (CCSA, 2025). The flip cards below give four snapshots from the same report; click each card to read it.
Nonmedical benzodiazepines, xylazine and medetomidine differ in chemistry, but they share a consequence that the final part of this section examines: they change what happens during and after an opioid overdose.
6.5 Why Sedative Adulterants Complicate Overdose and Withdrawal
When an opioid sample also contains a sedative from another class, the person who uses it is exposed to two or three depressants at once, usually without knowing it. This part explains the consequences for overdose, for safety during prolonged sedation, and for withdrawal.
6.5.1 Naloxone Restores Breathing but Not Alertness
Because naloxone acts only at opioid receptors, it can reverse the opioid component of a combined overdose and leave the sedation from xylazine, medetomidine or a benzodiazepine untouched. As of 2026, Canadian guidance therefore emphasizes that naloxone should still be given when opioid involvement is suspected, and that breathing is the sign used to judge whether it has worked, because a person may start breathing again long before they wake up (CCSA, 2023; CCSA, 2026). Section 4 explains the physiology behind this advice.
6.5.2 Risks During Prolonged Sedation
Prolonged sedation creates dangers beyond breathing. A person who is deeply sedated for hours is vulnerable to injury, assault and theft, and Canadian reports note that some people who use drugs respond to these risks by using alone, which greatly increases their risk of dying from drug toxicity because no one is present to respond (CCSA, 2023). Longer monitoring after an overdose needs staff, space and resources, and CCENDU sites reported strain on emergency departments and harm reduction services managing more complex presentations (CCSA, 2026).
6.5.3 Withdrawal from Sedative Adulterants
Regular exposure to a sedative produces physical dependence, so stopping, even unintentionally, can cause withdrawal. The box below summarizes what Canadian reports describe for each class; HSCI 402 develops withdrawal management in depth.
Withdrawal from sedative adulterants
Medetomidine. Withdrawal includes a fast heart rate (often above 120 beats per minute), high and sometimes severe blood pressure, nausea and vomiting, sweating out of proportion to usual opioid withdrawal, anxiety and restlessness, waxing and waning alertness, tremor and delirium. Canadian reports in 2026 described clonidine, a medicine that also acts on alpha-2 receptors, as the primary treatment, with dexmedetomidine in an intensive care unit for severe cases (CCSA, 2026). These descriptions come from early clinical reports, and a 2026 review noted that little is known about medetomidine withdrawal (Lynch et al., 2026). A person whose opioid supply contained medetomidine can go into withdrawal if medetomidine disappears from that supply, whether or not they knew it was there.
Xylazine. People who stop using opioids that contained xylazine can experience xylazine withdrawal, which has been treated with medicines of similar action, such as clonidine and dexmedetomidine (CCSA, 2023).
Nonmedical benzodiazepines. Regular use creates tolerance, and stopping, including by stopping opioids that contained benzodiazepines, can lead to life-threatening withdrawal; in Alberta, the CCENDU site linked the presence of nonmedical benzodiazepines to a higher risk of overdose and of severe withdrawal including seizures, and reported that desalkylgidazepam had become more prevalent (CCSA, 2025).
Interactive 5.3 asks you to sort the substances named in Sections 2 and 3 by the receptor system they act on, which also tells you whether naloxone will reverse their effects.
Suppose a drug checking result for a sample expected to be fentanyl lists four substances: fluorofentanyl, medetomidine, bromazolam and caffeine. Using Table 5.5 and Figure 5.4, work out for yourself which components naloxone would act on, which would continue to cause sedation after naloxone, which could cause withdrawal if they later disappeared from the person's regular supply, and why an FTIR spectrometer alone might have missed one of them. Suggested answer: naloxone acts only on the fluorofentanyl; medetomidine and bromazolam would continue to sedate; both could cause withdrawal if regular exposure stopped, with medetomidine withdrawal marked by high heart rate and blood pressure and benzodiazepine withdrawal carrying a risk of seizures; and medetomidine present at less than about 5 percent of the sample could be missed by FTIR.
Summary and Transition
By 2025, Canadian monitoring was finding sedatives that are not opioids in much of the unregulated opioid supply. Xylazine and medetomidine are veterinary alpha-2 agonists that cause sedation, a slow heart rate and low blood pressure; xylazine is linked to severe wounds, and medetomidine, which displaced it between 2024 and 2026 and reached 77 to 86 percent of expected fentanyl samples in Toronto in early 2026, is linked in early reports to severe and prolonged sedation and to a dangerous withdrawal syndrome. Nonmedical benzodiazepines such as bromazolam were found in about half of the fentanyl samples analyzed nationally in 2023 and 2024. None of these sedatives responds to naloxone. Section 4 explains how opioids stop breathing, how naloxone reverses them at the receptor, why it sometimes needs repeating, and what it cannot do when sedation persists.
Key Takeaways
- 6.1 An adulterant is a substance in a drug product other than the drug the buyer expected, and in an unregulated market with no quality control, new adulterants appear constantly and unpredictably. The sedatives that by 2025 were common in the Canadian opioid supply act on three receptor systems: opioids on the mu-opioid receptor, xylazine and medetomidine on alpha-2 adrenergic receptors, and benzodiazepine-type drugs on the GABA-A receptor. Their sedating effects add together, but naloxone acts only at the opioid receptor.
- 6.2 Xylazine is a veterinary alpha-2 adrenergic agonist that causes sedation, a slow heart rate and low blood pressure, and naloxone does not reverse it. Health Canada's Drug Analysis Service first identified it in 2019, and the share of fentanyl samples that also contained it reached about 12 percent in June 2022, the highest share in the period the report covered. Its most specific harm is skin ulcers and wounds with tissue death, which can appear away from injection sites and sometimes lead to amputation.
- 6.3 Medetomidine is a veterinary alpha-2 agonist about 100 to 200 times more potent than xylazine, causing severe and prolonged sedation, a slow heart rate and low blood pressure. Toronto's Drug Checking Service found it in 12 percent of expected fentanyl samples in August 2024 and 86 percent in February 2026, while in British Columbia xylazine fell from about 25 percent to 2 percent of tested opioid samples during 2025 as medetomidine rose. Responders reported longer sedation, more naloxone use and difficulty detecting it.
- 6.4 Nonmedical benzodiazepines are benzodiazepines and related drugs that are produced illegally or diverted, including novel ones not approved for the Canadian market, and they enhance the action of GABA at the GABA-A receptor. Bromazolam, first detected in British Columbia in 2021, became the most common in expected opioids there toward the end of 2022, and about half of the fentanyl samples analyzed nationally in 2023 and 2024 also contained a nonmedical benzodiazepine. Most exposure is unintended, and reported effects include prolonged sedation and memory loss.
- 6.5 Because naloxone acts only at opioid receptors, it can restore breathing while sedation from xylazine, medetomidine or a benzodiazepine continues, so breathing is the sign used to judge its effect. Prolonged sedation leaves a person vulnerable to injury, assault and theft, and using alone to avoid these risks raises the risk of death. Regular exposure creates dependence: early reports describe medetomidine withdrawal with a fast heart rate and high blood pressure, xylazine withdrawal has been treated with clonidine and dexmedetomidine, and benzodiazepine withdrawal can include seizures.
Reflection
Toronto's Drug Checking Service found medetomidine in 77 percent of expected fentanyl samples in March 2026, and 96 percent of the medetomidine-containing samples it checked between August 2024 and March 2026 also contained a high-potency opioid (CCSA, 2026). Imagine a hypothetical group of new volunteers at a community organization (not a real named service). Write a short explanation for them (150 to 250 words) of what medetomidine is and how it acts, why naloxone may restore a person's breathing without waking them, and why a person might go into severe withdrawal if medetomidine disappeared from their supply.
Minimum 20 characters required.
Question 1: How do xylazine and medetomidine produce sedation?
Question 2: Toronto's Drug Checking Service tracked medetomidine in samples expected to be fentanyl. What shares did it report for August 2024 and for February 2026, the highest month in its June 2026 summary?
Question 3: Which harm do Canadian reports link most specifically to xylazine?
Question 4: A person whose regular opioid supply contained medetomidine begins buying from a supply without it. What do Canadian reports warn may happen?
Overdose Physiology, Naloxone and Lost Tolerance
Content note. This section discusses how opioid overdoses cause death, and deaths after release from prison, including deaths by suicide. If you would like support, the 9-8-8 Suicide Crisis Helpline is available by call or text at 9-8-8, the National Overdose Response Service can be reached at 1-888-688-6677, and the Hope for Wellness Help Line for Indigenous people can be reached at 1-855-242-3310.
Introduction
This section brings the lesson's threads together at the moment of greatest danger: an overdose. It explains how opioids stop breathing, how naloxone reverses that effect, why the reversal can wear off, what naloxone cannot do when sedatives are present, and why people who have lost tolerance face especially high risk. HSCI 402 develops naloxone programs and the epidemiology of overdose deaths; the focus here is the pharmacology and physiology on which they rely.
Learning Objectives
- 7.1 Explain how opioids depress breathing by acting on respiratory regions of the brainstem, and describe the main signs of an opioid overdose.
- 7.2 Explain naloxone as a competitive antagonist at the mu-opioid receptor, and use a simple receptor-share ratio to show why larger or stronger opioid exposures need more naloxone.
- 7.3 Explain why an overdose can return when naloxone wears off before the opioid, why repeated doses may be needed after potent opioids such as nitazenes, and why excessive naloxone can precipitate withdrawal.
- 8.1 Explain why naloxone restores breathing but not alertness when sedative adulterants are present, and why breathing support and longer monitoring then matter.
- 8.2 Explain the high risk of overdose death in the weeks after release from prison, using the meta-analysis of Borschmann and colleagues (2024) and the studies of Binswanger and colleagues (2007) and Groot and colleagues (2016).
7.1 How Opioids Stop Breathing
Breathing is controlled automatically by the brainstem, where groups of nerve cells generate a regular rhythm, adjust its rate and depth, and respond to signals about carbon dioxide and oxygen in the blood. Opioids act directly on this control system, which is why respiratory depression is the main way an opioid overdose kills.
7.1.1 Opioid Receptors in the Breathing Centres
Opioid receptors are found in several regions of the brainstem involved in breathing. Opioids act on nerve cells in the Kölliker-Fuse nucleus and the preBötzinger complex, two parts of the network that generates the breathing rhythm, making these cells more negative inside (hyperpolarized) and reducing the release of glutamate, the excitatory messenger that drives respiratory neurons (Stucke et al., 2023). This is the quieting action of Figure 5.1, applied to cells whose job is to keep breathing going, and the overall depression of breathing results from combined effects on several regions (Stucke et al., 2023). The standard view is that opioids reduce the volume of air breathed each minute mainly by slowing the breathing rate, although studies collected in 2023 found more variation between individuals than this view suggests, so research on these mechanisms is evolving (Stucke et al., 2023). Figure 5.6 shows the control loop in simplified form.
Respiratory depression limits the use of opioids for pain relief, and Pattinson (2008), reviewing its mechanisms from the cellular level to the whole body, argued that better ways to counter it could benefit patients in pain and reduce deaths from opioid overdose. When breathing slows enough, oxygen in the blood falls and carbon dioxide rises. Intravenous fentanyl can also cause a stiffening of the chest and throat muscles, sometimes called wooden chest syndrome, that makes it hard to move air into the lungs at all (Stucke et al., 2023). Lesson 4 explained why other depressants deepen this effect, and Section 3 showed that by 2025 such combinations were common in the unregulated supply. 3-D Model 5.3 shows where mu-opioid receptors are found across the brain, using a map made with positron emission tomography (PET), a scanning method that measures where an injected radioactive tracer binds, and marks the preBötzinger complex and the Kölliker-Fuse nucleus in the brainstem.
7.1.2 Recognizing an Opioid Overdose
The physiology produces a recognizable pattern. The box below lists the signs described in Canadian guidance, and the changes that sedative adulterants add.
Signs of opioid toxicity
An opioid toxicity event typically involves slowed or stopped breathing (respiratory depression), unresponsiveness and pinpoint pupils. Canadian guidance on medetomidine, published in 2026, uses fewer than 12 effective breaths per minute, with opioid involvement suspected, as the threshold at which naloxone should be given. When medetomidine is also present, responders may see a slow heart rate, high blood pressure early on followed by low blood pressure, and sedation that continues after breathing improves (CCSA, 2026). HSCI 402 develops overdose response training and naloxone programs.
Because the cause of death in an opioid overdose is a receptor-level effect on breathing, it can be reversed at the receptor level. The next part explains how naloxone does this.
7.2 Naloxone and Competitive Antagonism
Naloxone is an opioid antagonist: it binds to opioid receptors without activating them. Pert and Snyder (1973) used it to find the opioid receptor (see Section 1, 2.1 The Body's Own Opioids and Their Receptors), and it is used to reverse opioid overdose (Health Canada, 2026).
7.2.1 What Naloxone Does
As of October 2026, Health Canada describes naloxone as working by knocking opioids off the receptors in the brain and binding to those receptors in their place. It can begin to take effect within about 2 minutes, it is available as a nasal spray and as an injection into a muscle, and take-home kits are available at most pharmacies without a prescription (Health Canada, 2026). Pharmacologists describe naloxone as a competitive antagonist: it competes with opioid agonists for the same binding site, and the receptor responds to whichever drug occupies it (Algera et al., 2019). Because the competition depends on how much of each drug is present, a larger amount of opioid needs a larger amount of naloxone to displace it.
7.2.2 A Simple Model of the Competition
The competition can be described with a simple ratio. Suppose each drug's amount at the receptor is expressed in binding units, where one unit is the concentration at which that drug, on its own, would occupy half of the receptors. In a simplified version of the standard description of competitive binding, the share of receptors occupied by the opioid is given by Equation 5.2.
Worked Example 5.2 uses hypothetical numbers to show how the model explains a reversal and its fading. All values are illustrative and are not attributed to any real drug or person.
Step 1, the overdose. An opioid is present at 19 units and no naloxone has been given. The opioid share is 19 ÷ (19 + 0 + 1) = 19 ÷ 20 = 95 percent of receptors, enough in this illustration to depress breathing severely.
Step 2, naloxone is given. Naloxone reaches 40 units. The opioid share falls to 19 ÷ (19 + 40 + 1) = 19 ÷ 60 = 31.7 percent, and breathing recovers.
Step 3, naloxone wears off first. Suppose, hypothetically, that the naloxone level halves every 30 minutes while the opioid level halves every 3 hours. After 60 minutes, naloxone has fallen to 10 units and the opioid to about 15.1 units, so the share is 15.1 ÷ (15.1 + 10 + 1) = 57.8 percent. After 120 minutes, naloxone is at 2.5 units and the opioid at about 12.0 units, so the share is 12.0 ÷ (12.0 + 2.5 + 1) = 77.4 percent, close to where breathing was dangerously depressed. A second dose of naloxone would be needed.
Step 4, a stronger exposure. If the opioid is present at 38 units (for example, a more potent batch), the same 40 units of naloxone lower the share only to 38 ÷ (38 + 40 + 1) = 48.1 percent. It would take about 80 units of naloxone to bring the share down to 38 ÷ (38 + 80 + 1) = 31.9 percent, roughly the level reached in Step 2.
Interactive 5.4 lets you change these hypothetical values and watch the opioid share of receptors over five hours, including a second dose and a sedative adulterant that naloxone cannot touch.
7.3 Why Naloxone May Need Repeating
The worked example and the interactive tool illustrate three reasons, each supported by Canadian or research sources. First, naloxone is active in the body for only 30 to 120 minutes, and Health Canada warns that its effects are likely to wear off before the opioids are gone, so breathing can stop again and naloxone may need to be given again (Health Canada, 2026). Second, a larger or more potent opioid exposure needs more naloxone: in early 2022 Canadian reports noted that overdoses involving nitazenes may be difficult to reverse and may need additional doses, although protocols were not yet clear (CCSA, 2022), and in 2026 responders in Alberta and Saskatchewan reported using more doses of naloxone in events linked to the supply at that time (CCSA, 2026). Third, a review of modelling studies of reversal in humans showed that naloxone's effect is limited by how quickly drugs reach and leave the receptor, and that there are conditions in which reversal is less effective or even impossible (Algera et al., 2019).
More naloxone is not always better. In a person who is physically dependent on opioids, naloxone abruptly removes the opioid effect and can trigger sudden, distressing withdrawal, called precipitated withdrawal, which Canadian guidance in 2026 warned can follow overly aggressive dosing (CCSA, 2026); a 2023 bulletin had already cautioned against giving naloxone repeatedly without benefit (CCSA, 2023). Table 5.6 brings together what naloxone does and what it cannot do.
Table 5.6. What naloxone does and what it cannot do, with sources.
| Property | What the sources report |
|---|---|
| Mechanism | Competitive antagonist that displaces opioids from their receptors (Algera et al., 2019; Health Canada, 2026) |
| Onset | Can begin to work within about 2 minutes (Health Canada, 2026) |
| Duration | Active for 30 to 120 minutes, often shorter than the opioid (Health Canada, 2026) |
| Effect on opioids | Restores breathing by reversing opioid effects; repeated doses may be needed (Health Canada, 2026) |
| Effect on xylazine, medetomidine and benzodiazepines | None; sedation from these drugs continues after opioid effects are reversed (CCSA, 2023; CCSA, 2026) |
| Risk of excess dosing | Precipitated withdrawal in people who are dependent on opioids (CCSA, 2026) |
The fifth row of Table 5.6, on sedatives that naloxone cannot reverse, gained importance in Canadian overdose response as medetomidine spread from 2024. The next part explains why.
8.1 When Sedation Persists
In an overdose involving an opioid alone, a successful naloxone response usually means that a person both breathes and wakes. With sedatives in the opioid supply, those two outcomes can separate.
8.1.1 Breathing Returns Before Consciousness
When an overdose involves an opioid and a non-opioid sedative, naloxone reverses the opioid's effect on the breathing centres, so breathing can return to normal, but the sedative continues to act on its own receptors. Canada's 2026 report on medetomidine summarized the result: in cases of profound sedation, breathing may return to normal after one dose of naloxone, while additional doses may not restore consciousness, and continued monitoring and transport to hospital may still be needed (CCSA, 2026). For this reason, as of 2026, Canadian guidance asks responders to use breathing as the indicator for giving naloxone and to avoid giving dose after dose in an attempt to wake a person whose breathing has recovered (CCSA, 2023; CCSA, 2026).
8.1.2 Why Breathing Support and Monitoring Matter
A person who is breathing but deeply sedated remains at risk. Sedation can last for hours, and in Alberta sometimes up to a week; medetomidine can also slow the heart and lower blood pressure (CCSA, 2026). A deeply sedated person may not keep their airway open or respond if breathing slows again as naloxone wears off, so services in Newfoundland and Labrador and New Brunswick reported placing greater emphasis on airway management, oxygen and longer monitoring (CCSA, 2026), and practice is still evolving as the supply changes. The accordion below applies the lesson to four types of event.
Naloxone displaces fentanyl, and breathing and alertness usually return together, but because naloxone is active for 30 to 120 minutes (Health Canada, 2026), respiratory depression can return as it wears off.
More opioid binding units must be displaced, so more naloxone may be needed, and the effect may return as naloxone fades. Canadian reports in 2022 noted that nitazene overdoses may require additional doses of naloxone, with protocols still unclear at the time (CCSA, 2022).
Naloxone restores breathing, but deep sedation, a slow heart rate and low blood pressure can continue, sometimes for a long time. As of 2026, no reversal agent for medetomidine is approved for humans, so care focuses on breathing, oxygen and monitoring, and later on the risk of severe withdrawal (CCSA, 2026).
Naloxone reverses the opioid but not the benzodiazepine, so sedation and memory loss can continue after breathing improves. Regular unintended exposure also creates a risk of benzodiazepine withdrawal, which can include seizures, if the supply changes (CCSA, 2025).
The cases so far concern what happens once an overdose has begun. The final part turns to a pattern that makes overdose more likely in the first place: a fall in tolerance.
8.2 Overdose After Lost Tolerance
Tolerance protects people who use opioids regularly from amounts that would stop the breathing of someone without it. When a person stops using for a period, for example during imprisonment, treatment or hospital care, that protection fades. If they then use an amount that they previously tolerated, or a supply that has become more potent in the meantime, the effect on their breathing can be much greater than they expect. This part describes the evidence on the period after release from prison.
Borschmann and colleagues (2024) combined linked records for 1,471,526 people released from incarceration in eight countries (Australia, Brazil, Canada, New Zealand, Norway, Scotland, Sweden and the United States) between 1980 and 2018, in an individual participant data meta-analysis of 18 cohort studies. The death rate in the first week after release was higher than in any later period, and in that week the leading causes were alcohol and other drug poisoning, suicide and cardiovascular disease. Rates and causes varied considerably across regions and over time since release (Borschmann et al., 2024). The two studies below, from Washington State and Ontario, illustrate the pattern in more detail.
8.2.1 Evidence from the United States
Ingrid Binswanger and colleagues (2007) followed all 30,237 people released from Washington State prisons between July 1999 and December 2003. Of these, 443 died during an average follow-up of 1.9 years. After adjustment for age, sex and race, former prisoners had 3.5 times the risk of death of other state residents (95 percent confidence interval 3.2 to 3.8). In the first 2 weeks after release, their risk of death was 12.7 times that of other residents (95 percent confidence interval 9.2 to 17.4), and their risk of death from drug overdose was 129 times as high (95 percent confidence interval 89 to 186). Drug overdose was the leading cause of death, followed by cardiovascular disease, homicide and suicide (Binswanger et al., 2007).
8.2.2 Evidence from Ontario
Case 5.3 describes a Canadian study that linked coroners' records to correctional records and examined the timing and circumstances of these deaths.
Groot and colleagues (2016) reviewed the files of the Office of the Chief Coroner for Ontario for 6,978 adults who died of drug toxicity between 2006 and 2013 and matched them with provincial correctional records. Of these deaths, 702, or about one in ten, occurred within one year of release from provincial incarceration. One in five of the 702 deaths (137) occurred within the first week after release, and 77 percent (538) involved one or more opioids. In 318 of the opioid-related deaths (59 percent), the circumstances suggested that another person could have intervened. The authors attributed the high early risk partly to drug use after a period of abstinence that had led to a loss of tolerance (Groot et al., 2016).
A 2019 review by Joudrey and colleagues placed lost tolerance within a wider model of risk after release: interrupted treatment, including access to medications for opioid use disorder, polydrug use, limited access to naloxone and a return to using alone lead to reduced respiratory tolerance and overdose, and the spread of fentanyl has added a further risk (Joudrey et al., 2019).
The same mechanism applies to other transitions. A British Columbia study of non-fatal overdose summarized earlier research showing that recent release from prison and recent discharge from hospital have each been associated with an increased risk of fatal overdose (Keen et al., 2021). Lesson 11 develops the role of incarceration in drug policy, and HSCI 402 develops naloxone distribution and care after release.
Using Case 5.3, explain to yourself in three or four sentences why the first week after release carries the highest risk, naming tolerance and linking it to the supply described in Section 2. A strong explanation notes that tolerance fades during abstinence, that a person may return to an amount they used before, and that the supply may have become more potent in the meantime, so the same amount can depress breathing far more than expected.
Summary
Opioids stop breathing by quieting brainstem nerve cells that generate the breathing rhythm. Naloxone competes with opioids for the mu receptor; a simple receptor-share ratio shows why larger or more potent exposures need more naloxone and why breathing can fail again when naloxone wears off first. Naloxone cannot reverse sedation from xylazine, medetomidine or nonmedical benzodiazepines, so breathing support and monitoring matter. People who have lost tolerance, especially soon after release from prison, face a sharply higher risk of death.
On 28 January 2026, Saskatchewan's Ministry of Health issued a drug alert reporting six overdoses over 48 hours. Many of the people affected needed multiple doses of naloxone, they experienced heavy sedation and difficulty breathing, and some required medical care that included oxygen. No direct link to medetomidine was confirmed, but one drug sample associated with the alert tested positive for both fentanyl and medetomidine. Health Canada's seized-drug data showed the share of Saskatchewan samples containing medetomidine, fentanyl and fentanyl analogues rising from 0 percent (0 of 54) in 2024 to 77.3 percent (17 of 22) in January to March 2026 (CCSA, 2026).
Work through the case using each section of the lesson. (1) Section 1: which drug in the sample acts on the mu-opioid receptor, and which does not? (2) Section 4: give two reasons, at the receptor level, why multiple doses of naloxone might have been needed. (3) Sections 3 and 4: why could heavy sedation continue after naloxone, and why would oxygen and monitoring help? (4) Section 2: what kind of evidence links medetomidine to these events, which monitoring source produced the 77.3 percent figure, and what limits would stop you from concluding that medetomidine caused these six events? Key ideas: fentanyl is the opioid and medetomidine an alpha-2 agonist; naloxone may wear off before the opioid, and stronger exposures need more naloxone; medetomidine's sedation does not respond to naloxone, so breathing support and monitoring matter; and neither the test of one sample nor the Drug Analysis Service's seized-drug data confirms what each person took, while no clinical test for medetomidine was available.
Key Takeaways
- 7.1 Breathing is generated automatically by brainstem networks such as the preBötzinger complex and the Kölliker-Fuse nucleus, and opioids quiet these cells and reduce glutamate release, slowing breathing until carbon dioxide rises and oxygen falls. Respiratory depression is the main way an opioid overdose kills. Its signs include slowed or stopped breathing, unresponsiveness and pinpoint pupils, and Canadian guidance published in 2026 uses fewer than 12 effective breaths per minute, with opioid involvement suspected, as the threshold for giving naloxone.
- 7.2 Naloxone is a competitive antagonist that displaces opioids from their receptors and can begin to work within about 2 minutes. In the simplified receptor-share model (Equation 5.2), opioid share = opioid units ÷ (opioid units + naloxone units + 1), so 19 opioid units occupy 95 percent of receptors before naloxone and 31.7 percent after 40 units of naloxone. A larger or more potent opioid exposure needs more naloxone to reach the same share.
- 7.3 Naloxone is active for only 30 to 120 minutes and often wears off before the opioid, so breathing can fail again and a second dose may be needed. Overdoses involving potent opioids such as nitazenes may need additional doses, and modelling studies show conditions in which reversal is less effective. More naloxone is not always better, because overly aggressive dosing can trigger precipitated withdrawal in people who are dependent on opioids.
- 8.1 When an overdose involves an opioid and a non-opioid sedative, naloxone can restore breathing while the sedation continues, sometimes for hours and, in Alberta, up to a week. As of 2026, Canadian guidance therefore uses breathing, not wakefulness, to judge naloxone and advises against giving dose after dose to wake a person. Because a deeply sedated person may not keep their airway open and may stop breathing again as naloxone wears off, airway management, oxygen and longer monitoring matter.
- 8.2 Tolerance fades when a person stops using, so a previously tolerated amount, or a supply that has become more potent in the meantime, can depress breathing far more than expected. Binswanger and colleagues found that people released from Washington State prisons had 129 times the risk of overdose death of other residents in the first 2 weeks, and Groot and colleagues found that one in five post-release drug toxicity deaths in Ontario occurred within the first week. Recent discharge from hospital has also been associated with an increased risk of fatal overdose.
The reflection and knowledge check below, and then the final assessment, ask you to use these ideas together. Lesson 6 turns to the stimulants, which Section 2 showed were involved in 71 percent of opioid deaths in Canada in 2025.
Reflection
Groot and colleagues (2016) found that 702 of 6,978 drug toxicity deaths among adults in Ontario between 2006 and 2013 occurred within one year of release from provincial incarceration; 137 of these occurred in the first week, and 77 percent involved opioids. In 150 to 250 words, use the idea of tolerance, the receptor-share model in Equation 5.2 (opioid share = opioid units ÷ (opioid units + naloxone units + 1)) and what you know about the current unregulated supply to explain why the first week after release is so dangerous. Then name one other transition in a person's life that could carry a similar risk, and explain why.
Minimum 20 characters required.
Question 1: Using Equation 5.2, if an opioid is present at 9 binding units and naloxone at 20 units, what share of receptors does the opioid occupy?
Question 2: Why can an opioid overdose return after naloxone has restored a person's breathing?
Question 3: A person who used an opioid mixed with medetomidine is breathing adequately after one dose of naloxone but remains very hard to wake. According to Canadian guidance, what should guide any further naloxone?
Question 4: In Binswanger and colleagues' (2007) study of people released from Washington State prisons, how did the risk of death from drug overdose in the first 2 weeks after release compare with that of other state residents?
Final Assessment
Bringing It All Together
This lesson followed opioids from a single receptor to a national crisis. Opioids act on a receptor system that the body uses for its own peptides: activating the mu-opioid receptor quiets nerve cells, which relieves pain and produces euphoria but also slows breathing as the amount rises. Morphine, heroin, fentanyl, carfentanil and the nitazenes share this mechanism and differ chiefly in potency, so that an effect produced by 10,000 grains of morphine can be matched by 100 to 200 grains of fentanyl or a single grain of carfentanil.
Potency became deadly when it entered an unregulated market. Ciccarone's triple wave model describes a crisis that moved from prescription pills to heroin to illicitly manufactured fentanyl, with stimulants involved in 71 percent of opioid deaths in Canada in 2025. In British Columbia, fentanyl rose from about 5 percent of drug deaths in 2012 to more than 90 percent by 2018, and fentanyl analogues and sedative adulterants have followed. A 2021 review and a 2019 RAND report attribute these changes mainly to suppliers, although demand was mixed, and Canada tracks them through seized-drug analysis, drug checking, post-mortem toxicology, wastewater testing and sentinel networks, each with blind spots.
The sedatives that by 2025 were common in the opioid supply, xylazine, medetomidine and nonmedical benzodiazepines such as bromazolam, act on receptors that naloxone does not touch. Naloxone remains the essential treatment for the opioid component of an overdose, but it can wear off before the opioid, may need repeating after potent exposures, and cannot restore alertness when sedatives are present. People whose tolerance has fallen, especially in the weeks after release from prison, face a sharply higher risk.
Key Takeaways from this lesson
- Opioid is the general term for any substance that acts on opioid receptors, and opioid drugs fall into natural, semi-synthetic, synthetic and novel synthetic families; as of September 2026, the main ones are controlled under Schedule I of the Controlled Drugs and Substances Act, while morphine and fentanyl are also prescription medicines.
- Opioids act on a receptor system the body uses for its own peptides, and the mu-opioid receptor is the main target of the opioids in the Canadian supply. Activating it quiets nerve cells by blocking calcium channels and opening potassium channels, which produces pain relief and euphoria and, at higher amounts, slowed breathing; full agonists, partial agonists and antagonists differ in how far they switch it on.
- Potency is the mass needed for an effect and efficacy is the largest effect possible; fentanyl is 50 to 100 times more potent than morphine, and carfentanil is described as about 10,000 times more potent. Potency becomes dangerous in an unregulated supply because small, invisible mixing errors become large changes in the dose of opioid.
- The triple wave model describes a United States crisis that moved from prescription pills to heroin to illicitly manufactured fentanyl, with a fourth wave involving stimulants. In British Columbia, fentanyl rose from about 5 percent of illicit drug deaths in 2012 to 87 to 94 percent of opioid deaths from 2017 to 2022, fentanyl analogues have since become common, and a 2021 review and a 2019 RAND report attribute the shift mainly to supplier decisions.
- Agencies name and count drug deaths differently, so a figure should be cited with its agency, definition and date. Canada monitors the supply through seized-drug analysis, drug checking, toxicology, wastewater testing and sentinel networks, each with a strength and a blind spot.
- Xylazine and medetomidine are alpha-2 agonists and nonmedical benzodiazepines act at the GABA-A receptor; none responds to naloxone, medetomidine largely displaced xylazine between 2024 and 2026, and each class brings distinctive harms such as wounds or severe withdrawal.
- Opioids slow breathing by quieting brainstem breathing centres. Naloxone is a competitive antagonist that lasts 30 to 120 minutes, so overdoses can return and stronger exposures may need more naloxone.
- When sedatives are present, naloxone can restore breathing without restoring alertness, so breathing is the sign used to judge its effect and monitoring matters. A 2024 meta-analysis found death rates highest in the first week after release from prison, and a 2019 review places lost tolerance in a chain of risk that also includes interrupted treatment and using alone.
Core Concepts Reviewed
Section 1: opiates and opioids, the endogenous opioid system, the mu-opioid receptor and its G protein signalling, full and partial agonists and antagonists, tolerance, potency, efficacy and relative potency.
Section 2: drug toxicity, overdose and poisoning as terms, the triple wave model and the fourth wave, the supply-side account of fentanyl, fentanyl analogues and nitazenes, and the sources that monitor the composition of the supply.
Section 3: adulterants, alpha-2 adrenergic agonists (xylazine and medetomidine), nonmedical benzodiazepines such as bromazolam, prolonged sedation, xylazine wounds and withdrawal from sedative adulterants.
Section 4: opioid-induced respiratory depression in the brainstem, naloxone as a competitive antagonist, the receptor-share model, repeated dosing, precipitated withdrawal, persistent sedation and overdose after lost tolerance.
The final reflection asks you to bring the four sections together by tracing a single hypothetical sample from receptor to supply to overdose response.
Reflection
Consider a hypothetical sample sold as fentanyl that a drug checking service finds to contain fluorofentanyl, medetomidine and bromazolam. In 200 to 250 words, integrate the four sections of this lesson: (1) explain how each component acts at its receptor; (2) explain how such a mixture came to be in the Canadian supply and which monitoring sources would detect it, with one limit; (3) explain what would happen during an overdose involving this sample and what naloxone could and could not do; and (4) identify one group of people at especially high risk from this sample and explain why.
Minimum 30 characters required.
Final Knowledge Assessment
Question 1: Why does a mixing error in an unregulated batch matter far more for carfentanil than for heroin?
Question 2: Which pairing correctly matches a receptor with a substance found in the Canadian unregulated opioid supply?
Question 3: Pert and Snyder (1973) used radioactively labelled naloxone to demonstrate the opiate receptor. Why does the same property make naloxone useful in an overdose?
Question 4: PHAC data show the share of Canada's apparent opioid toxicity deaths involving fentanyl analogues rising from 10 percent in 2018 to 60 percent in 2025. What does this indicate about the supply?
Question 5: The BC Coroners Service reported 1,826 unregulated drug toxicity deaths in British Columbia for 2025, while PHAC reported 1,855 apparent opioid toxicity deaths in the province for the same year. What best explains the difference?
Question 6: Which feature of the spread of fentanyl best fits the supply-side account given by Ciccarone (2019) and Pardo and colleagues (2019)?
Question 7: A sample expected to be fentanyl contains fluorofentanyl, medetomidine and bromazolam. Which component would naloxone reverse?
Question 8: Why might Canadian post-mortem toxicology have undercounted the involvement of some newer substances in deaths?
Question 9: Hypothetically, an opioid is present at 38 binding units and naloxone at 40 units. Using Equation 5.2, what is the opioid's share of receptors, and what does it suggest?
Question 10: Which group faced a risk of overdose death about 129 times that of other residents in the first 2 weeks of follow-up, and what mechanism best explains it?
Question 11: When medetomidine may be present, why does Canadian guidance use breathing as the sign for judging whether naloxone has worked?
Question 12: Which statement about nonmedical benzodiazepines in Canada is supported by CCSA (2025)?
Question 13: Which monitoring source is generally the most timely and the most closely linked to what a person expected to buy?
Question 14: Ciccarone (2019) argued that changes in potency, purity and mixture in the fentanyl market may be even more dangerous than fentanyl's potency. Why?
Question 15: Which sequence correctly orders the waves of the United States opioid crisis described by Ciccarone (2019) and extended by Ciccarone and Shoptaw (2022)?
Glossary: Key Terms, People & Frameworks
📚 Reference page, available throughout the lesson
Terms, tools and people introduced in this lesson on opioids and the toxic unregulated drug supply, with short definitions.